A study monitored pregnancy and treatment outcomes for women with mpox during the outbreak in the United States from August to December 2022. Thirteen health departments tracked 26 pregnant or recently pregnant women with confirmed mpox infections through the SET-NET program. Of the 23 women with known outcomes, 19 had live births, three of which were preterm, and four experienced pregnancy losses. Infections occurred at different stages: six in the first trimester, nine in the second, and eight in the third. Fourteen women were treated with tecovirimat under an Investigational New Drug protocol, and no adverse effects were reported. Two neonates were diagnosed with mpox shortly after birth, with their mothers testing positive shortly after delivery. Both infants were treated with tecovirimat, and one received additional therapy without serious side effects, aside from a suspected rash in one case. The study concluded that there were no adverse maternal outcomes among the women studied, and the relationship between tecovirimat and pregnancy outcomes could not be assessed due to the small sample size.